Review Article
The Effect of Hepatosteatosis on Response to Antiviral Treatment in Patients with Chronic Hepatitis B: A Meta-Analysis
Table 2
Baseline biochemical levels in the trials included in the meta-analysis.
| | Biochemical baseline (IU/L) | Baseline HBV DNA level (log10 copies/mL) | Patients with HBeAg(+) (%) | | Study | With hepatosteatosis | Without hepatosteatosis | With hepatosteatosis | Without hepatosteatosis | With hepatosteatosis | Without hepatosteatosis |
| | Cindoruk et al. [16] | ALT 105 ± 75▲ | ALT 155 ± 39 | NA | NA | HBeAg(+) 68.8% | HBeAg(+) 70.7% | | AST 111 ± 64▲ | AST 132 ± 49 | | Ates et al. [13] | ALT 128.3 ± 18.9▲▲ | ALT 139.2 ± 52.5 | 3.72 ± 3.38 | 3.74 ± 4.12 | HBeAg(+) 21.1% | HBeAg(+) 26.2% | | AST 90.7 ± 34.8 | AST 107 ± 40.3 | | Shi et al. [19] | ALT 142.5 ± 84.1 | ALT 177.1 ± 138.3 | 6.96 ± 1.27▲ | 7.54 ± 1.28 | HBeAg(+) 100% | HBeAg(+) 100% | | AST 72.9 ± 35.3▲ | AST 99.5 ± 72.3 | | Jin et al. [18] | ALT 171.68 ± 46.23 | ALT 159.18 ± 45.12 | 6.69 (5.94–7.50) | 6.65 (5.18–7.51) | HBeAg(+) 58.5% | HBeAg(+) 64.2% | | AST 59.66 ± 13.81 | AST 56.63 ± 13.13 | | Chen et al. [14] | ALT 250.5 ± 145.2 | ALT 286.0 ± 210.2 | 6.8 ± 1.2 | 6.9 ± 1.1 | HBeAg(+) 100% | HBeAg(+) 100% | | AST 149.1 ± 101.8 | AST 168.7 ± 144.2 | | Chen et al. [15] | NA | NA | NA | NA | NA | NA | | Gong et al. 2015 [17] | ALT 143.3 ± 82.1 | ALT 157.1 ± 82.1 | 6.7 ± 1.2 | 7.4 ± 1.2 | HBeAg(+) 100% | HbeAg(+) 100% | | AST 70.2 ± 33.7 | AST 70.2 ± 33.75.3 | | Xu et al. [20] | ALT 119.2 ± 118.1 | 108.4 ± 75.2 | 5.8 ± 1.2 | 5.7 ± 1.2 | HBeAg(+) 67.9% | HBeAg(+) 68.2% |
|
|
ALT: alanine aminotransferase; AST: aspartate aminotransferase; NA: not available; ▲; ▲▲.
|
